[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?

Moreno-Ramírez, D; Fernández-Orland, A; Ferrándiz, L

Moreno-Ramírez, D; Fernández-Orland, A; Ferrándiz, L.

Affiliation

Moreno-Ramírez D; Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain. Electronic address: dmoreno@e.derma-org.
Fernández-Orland A; Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain.
Ferrándiz L; Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain.

Actas Dermosifiliogr ; 115(1): T48-T55, 2024 Jan.

Article in En, Es | MEDLINE | ID: mdl-37923078

Subject(s)

Melanoma; Skin Neoplasms; Humans; Melanoma/drug therapy; Melanoma/genetics; Proto-Oncogene Proteins B-raf/genetics; Nivolumab/therapeutic use; Nivolumab/genetics; Immunotherapy; Mutation; Skin Neoplasms/drug therapy; Skin Neoplasms/genetics; Molecular Targeted Therapy

Key words

Adjuvant treatment; Anti-CTLA4; Anti-PD1; BRAF inhibitors; BRAF-MEK inhibitors; CTLA4 inhibitors; Immunotherapy; Inhibidores de BRAF; Inhibidores de BRAF-MEK; Inmunoterapia; Melanoma; Neoadjuvant therapy; PD1 inhibitors; Targeted therapy; Terapias dirigidas; Tratamiento adyuvante; Tratamiento neoadyuvante

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Limits: Humans Language: En / Es Journal: Actas Dermosifiliogr Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google